glp-1 dementia receptor agonists effect on cognitive function in patients with and without type 2 diabetes Interest in using GLP-1 medications

Conclusion The trend of microdosing GLP-1 drugs like Ozempic and Wegovy has gained attention due to its potential for minimizing side effects, lowering costs, and promoting gradual weight loss

GLP-1 (glucagon-like peptide 1) is a receptor agonist, a class of drugs originally designed to treat type 2 diabetes, with brand names such as Ozempic, Wegovy, and Mounjaro

Supported by modern medical research, - -- & has passed the FDAs rigorous regulatory review and certification, with its effectiveness and compliance officially validated

Table of Contents: What is Ozempic

Human studies will need to establish durability, tolerability (esp